Richard Chau is a journalist for GeneOnline, specializing in covering the latest advancements and trends in the field of biotechnology and life sciences. With a focus on international business partnerships, medical conferences, and breakthrough therapies, Richard provides insightful coverage of the industry's most significant developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Richard Chau's articles predominantly cover the healthcare and pharmaceutical industry, focusing on medical advancements, biotechnology, and industry-specific events. His coverage includes expert commentary and announcements related to these topics.
To effectively reach out to Richard Chau, consider providing expert insights into recent breakthroughs in medical technology or significant developments within the pharmaceutical or biotech industries. Additionally, offering commentary on mergers and acquisitions in the healthcare sector may capture his interest based on his coverage focus.
Given that Chau often provides event coverage from healthcare conferences such as JPM 2024 and MedTex Summit Asia 2023, professionals involved in organizing or speaking at such events might be valuable sources for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Richard Chau
Published in the April 12 issue of Science Advances, engineers from Rice University have recently developed the smallest implantable brain stimulator ever demonstrated in a human patient, marking a significant advancement in the treatment of depression and various neurological disorders.
By: Richard Chau
Scientists at the University of California, Riverside (UC Riverside) have recently unveiled a groundbreaking RNA-based vaccine strategy that could revolutionize vaccination efforts against a myriad of viruses.
By: Richard Chau
Published in Nature Metabolism, UC Berkeley researchers recently presented new evidence that lactate serves as a vital component in managing carbohydrate metabolism, debunking the myth that lactate formation signals oxygen deprivation in muscles.
By: Richard Chau
On May 21, Eli Lilly and Company announced a $1.16 billion, multi-target drug discovery collaboration with Aktis Oncology, a biotech company specializing in novel targeted radiopharmaceuticals for solid tumors.
Following the success of previous years, Taiwan's Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), MOEA will participate in BIO 2024 by organizing a Taiwan delegation with over 60 delegates and accompanying organizations.
By: Richard Chau
On July 3, the Science and Technology Law Institute (STLI) organized a webinar on global regulatory trends in regenerative medicine. Dr. Shin Kawamata, CEO of Cyto-Facto, a Japanese cell and gene therapy CDMO company, and Dr. Christopher Tsai, Chairman of the BIONET Group, were invited as speakers for the event.
By: Richard Chau
Webinar Series on International Regulatory Affairs: The major regulatory issues and challenges related to nucleic acid drugs.
STLI organized the webinar themed “Pharmaceutical Innovations with AI/ML and Digital Technology” on August 21 in cooperation with GeneOnline.
By: Richard Chau
Illumina's TruSight Oncology (TSO) Comprehensive is the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims, which can detect variants in 517 genes across nearly 30 solid tumor types.
By: Richard Chau
Organized by the Taiwan Creative Economy Association (TCEA), the 2024 International Green Party was held from 14 to 15 September. Under the theme of “AI Solutions: Accelerating the Path to SDGs?”, this year's event brought together global experts to explore how AI can bring impetus to sustainable development.
(833) 317-6278 
